Decipher Genomics Resource for Intelligent Discovery
- Conditions
- Bladder CancerRenal CancerProstate Cancer
- Interventions
- Other: Decipher Cancer Classifier
- Registration Number
- NCT02609269
- Lead Sponsor
- GenomeDx Biosciences Corp
- Brief Summary
To prospectively evaluate the utility of genomic expression data as a tool to better characterize the tumors of individual patients, and to understand how genomic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.
- Detailed Description
Observational study involving the release of tumor genome-wide expression data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics of cancer and discover or validate gene expression signatures that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 1000000
Subjects that have had a Decipher clinical test
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Decipher GRID Patients Decipher Cancer Classifier Patients who have been tested with any of the Decipher clinical tests
- Primary Outcome Measures
Name Time Method Link complete genomic RNA expression array data generated from Decipher testing with clinical data for patients who consent to participate. Through study completion, an average of 1 year Role of genomic expression data in the biology of certain cancers
- Secondary Outcome Measures
Name Time Method